ArticleJournal of clinical practice and research2025
Pulmonary Mucormycosis with Endobronchial Involvement Complicated by Pleural Effusion.
Article in Journal of clinical practice and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transection of the Right Intermediate Bronchus Caused byInfection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary mucormycosis is an infection caused by a fungus with a severe and often fatal course, with a mortality rate exceeding 50%. It can spread through blood or lymphatic fluids or by inhalation of sporangiospores. Immunocompromised patients are especially susceptible to this high mortality rate. Histopathology is used to identify nonseptate hyphae in tissue, and culture is used to confirm the diagnosis. Treatment usually involves a combination of aggressive surgery and medication. Case Report: A patient with diabetes mellitus received corticosteroid treatment for facial paralysis, which led to the diagnosis of pulmonary mucormycosis. Without requiring surgical resection, the patient was successfully treated with intravenous antifungal medication, along with intrabronchial and intrapleural liposomal amphotericin B. Conclusion: Pulmonary mucormycosis requires prompt diagnosis and treatment. Close monitoring of such infections may minimize the need for invasive procedures and lower mortality, particularly when endobronchial involvement accompanied by effusion is present.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.